Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.

Autor: Lentz, S. R.1 steven-lentz@uiowa.edu, Cerqueira, M.2, Janic, D.3, Kempton, C.4, Matytsina, I.5, Misgav, M.6, Oldenburg, J.7, Ozelo, M.8, Recht, M.9, Rosholm, A.5, Savic, A.10, Suzuki, T.11, Tiede, A.12, Santagostino, E.13
Zdroj: Haemophilia. Sep2016, Vol. 22 Issue 5, pe445-e449. 5p. 1 Illustration, 1 Graph.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje